Evidence map›Paper›PMID 38113463›Full record

ArticleBlood advances2024

ZAP-70 augments tonic B-cell receptor and CCR7 signaling in IGHV-unmutated chronic lymphocytic leukemia.

Jingyu Chen, Vijitha Sathiaseelan, Chandra Sekkar Reddy Chilamakuri, Valar Nila Roamio Franklin, Constanze A Jakwerth, Clive D'Santos, Ingo Ringshausen

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jingyu ChenDepartment of Biochemistry and Molecular Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, People's Republic of China.ORCID 0000-0002-1941-8621
Vijitha SathiaseelanWellcome/MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.
Chandra Sekkar Reddy ChilamakuriCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Valar Nila Roamio FranklinCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Constanze A JakwerthCenter of Allergy & Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health & German Center for Lung Research (DZL), Munich, Germany.
Clive D'SantosCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Ingo RingshausenWellcome/MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-7247-311X
University of Cambridge · GBWellcome/MRC Cambridge Stem Cell Institute · GBHelmholtz Zentrum München · DE

Funding

Cancer Research UK 17480Cancer Research UK CRI_CORE_BIOIN_2324Cancer Research UK CRI_CORE_PROTE_2324
6 · The paper itself

Abstract

abstractExpression of ZAP-70 in a subset of patients with chronic lymphocytic leukemia (CLL) positively correlates with the absence of immunoglobulin heavy-chain gene (IGHV) mutations and is indicative of a more active disease and shorter treatment-free survival. We recently demonstrated that ZAP-70 regulates the constitutive expression of CCL3 and CCL4, activation of AKT, and expression of MYC in the absence of an overt B-cell receptor (BCR) signal, bona fide functions of BCR activation. We, here, provide evidence that these features relate to the presence of a constitutive tonic BCR signal, exclusively found in IGHV-unmutated CLL and dependent on the ZAP-70-mediated activation of AKT and its downstream target GSK-3β. These findings are associated with increased steady-state activation of CD19 and SRC. Notably this tonic BCR signal is not present in IGHV-mutated CLL cells, discordantly expressing ZAP-70. Results of quantitative mass spectrometry and phosphoprotein analyses indicate that this ZAP-70-dependent, tonic BCR signal regulates CLL cell migration through phosphorylation of LCP1 on serine-5. Indeed, we show that CCL19- and CCL21-induced chemotaxis is regulated by and dependent on the expression of ZAP-70 through its function to enhance CCR7 signaling to LCP1. Thus, our data demonstrate that ZAP-70 converges a tonic BCR signal, exclusively present in IGHV-unmutated CLL and CCR7-mediated chemotaxis.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellGlycogen Synthase Kinase 3 betaHumansProto-Oncogene Proteins c-aktReceptors, CCR7Signal TransductionCCR7 protein, humanGlycogen Synthase Kinase 3 betaProto-Oncogene Proteins c-aktReceptors, CCR7

Identifiers

PMID38113463
PMCPMC10910066
OpenAlexW4389978417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.